Non-members: Click here to review a complimentary excerpt from “Patient Advocacy Excellence: Optimizing Functional Structure & Managing Advocacy Relationships”
Patient advocacy groups are an important part of educating the marketplace on the latest medicines and treatments. Collaborating with advocacy groups is particularly vital for educating the public on socially-sensitive conditions and treatment options. Consequently, successful biopharmaceutical organizations seek better ways to collaborate and manage relationships with key patient and professional advocacy groups.
Best Practices, LLC undertook this benchmarking research to identify effective practices in patient advocacy group collaboration and relationship management. This study examines winning strategies, best practices, preferred structures, resource levels, responsibilities, collaboration approaches and lessons learned in patient advocacy collaboration.
- Patient Advocacy Functional Structure
- Patient Advocacy Partner Coordination & Effectiveness
- Developing & Optimizing Patient Advocacy Partnerships
- Managing Relationships Within Controversial Disease States
- Structure of Patient Advocacy Function within Participating Companies & its Efficacy
- Process Used to Communicate with External Advocacy Groups
- Number of FTEs Dedicated to Patient Advocacy Activities
- Number of Advocacy Groups Supported by Participating Companies
- Effective Metrics for Measuring the Success of Patient Advocacy Activities and Relationships
- Effective Approaches Used to Coordinate Relationships with Advocacy Groups
- Importance of Advocacy Collaborations at Different Lifecycle Stages
- Education, Support Programs, and Grants/Sponsorships Used During Key Lifecycle Stages
- Effective Approaches to Seed an Early Relationship with Patient Advocacy Groups
- Critical Collaboration Issues when Working with Advocacy Groups on Potentially Controversial Therapies
- Effective Approaches in Educating the Market on Conditions that May be Highly Controversial or Have a Social Stigma
- Impact of Special Interest Groups
- Most Effective Strategy or Tactics in Minimizing Opposition from Patient Advocacy or Other Special Interest Groups against a Therapy that could be Considered Controversial
SAMPLE KEY FINDINGS
- Structuring High Performance Bio-Pharma Advocacy Groups: Companies participating in this study did not favor one type of organizational structure for their patient advocacy groups. The structural approach of participants’ advocacy organizations ranged between decentralized therapeutic area-focused groups, centralized groups and those with a hybrid structure. More than half of the companies consider their advocacy group structure effective. More than half of the companies who consider their structure effective use a centralized approach. Moreover, of the 11 companies that consider their structure ineffective, 45% would like to adopt a centralized structure to improve their operations.
Best Practices, LLC engaged 24 leaders from 21 top bio-pharmaceutical companies through a benchmarking survey. In-depth interviews were conducted to gather more detailed information pertinent to this study. More than 50% of participants are at the director/ senior director level. More than 70% of participants are from the United States.